Avantage majeur rapporté et faisant tout l’intérêt de ce stent: la motricité vasculaire est restaurée à 12 mois et se révèle supérieure à celle observée avec le stent classique, grâce à la résorption du biopolymère faisant la liaison entre les structures métalliques du dispositif qui se retrouvent alors indépendantes les unes des autres, apportant ainsi de la souplesse au stent.

HF hospitalization rates and symptom burdens remain high in patients with HF. In addition to drug therapy, several interventional procedures for neuromodulation have been increasingly investigated in patients with HF. This article summarizes the pathophysiologic rationale and latest clinical evidence for interventional neuromodulating therapies investigated in HF, including catheter-based renal sympathetic denervation (RDN), unilateral electrical baroreflex activation therapy (BAT), and endovascular BAT

Autonomic modulation has been proposed as a potential therapeutic strategy aimed at reduction of systemic inflammation. Such therapies, complementary to drug and device-based therapies may lead to improved patient outcomes and reduce disease burden. Most professional societies currently do not provide a clear recommendation on the use of neuromodulation techniques in HF. These include direct and indirect vagal nerve stimulation, spinal cord stimulation, baroreflex activation therapy, carotid sinus stimulation, aortic arch stimulation, splanchnic nerve modulation, cardiopulmonary nerve stimulation, and renal sympathetic nerve denervation. In this review, we provide a comprehensive overview of neuromodulation in HF.

EDTA-3Na/H2O or EDTA-2Na/H2O with longer circulation times resulted in greater calcium reduction in atherosclerotic lesion. EDTA may have a potential therapeutic option for the treatment of atherosclerotic calcified lesions.

Chelation therapy works by administering chelating agents that bind to heavy metals and safely remove them from the body through the urine. These compounds work by forming multiple chemical bonds to a metal ion.

The investigation underscores the significance of corrosion resistance and biocompatibility in diverse anatomical cavities. The quintessential biodegradable Mg stent ought to possess stellar mechanical properties, biodegradability, and commendable biocompatibility while taking into account site-specific requisites. The utilization of degradable stents obviates the necessity for secondary interventions and proffers unparalleled advantages in disparate luminal environments. Mg alloys have garnered attention as exceedingly promising materials for multifaceted human implants, owing to their mechanical attributes and degradation kinetics. Nevertheless, challenges such as mechanical support duration, degradation kinetics, biological functionality, and compatibility with minimally invasive therapeutic modalities necessitate redressal for prospective device translation.

The disadvantages of Mg-based stents include their rapid degradation and insufficient endothelialization after implantation. Bioinspired strategies for Mg-based stents can increase not just the corrosion resistance but also their biocompatibility. For instance, bioinspired strategies would exhibit slow degradation by constructing a bioinspired physical barrier to prevent exposure of Mg-based stents to the ambient atmosphere and achieve fast endothelialization after implantation to tackle restenosis problems.

These findings suggest that low LDL-C levels are associated with an increased bleeding risk within 3 months among patients with minor ischemic stroke or high-risk transient ischemic attack who are receiving dual antiplatelet therapy, especially those taking ticagrelor-aspirin.

The preliminary findings confirmed the proposed smart stent's higher level of structural integrity, durability and repeatability. Finally, the practical feasibility of the smart stent is demonstrated by monitoring diastole and systole at various beat rates using a phantom. The results of the phantom study showed a similar pattern to the human model, indicating the potential use of the proposed multifunctional smart stent for real-time applications.

The stent may be used as an antenna coil and may replace supplemental circular or planar coils for receiving power. The stent shape and dimensions may be modified to allow them to receive energy and also provide longer life, thereby having a longer-term treatment. This study is expected to introduce a key database of associated works for researchers in the field. Lastly, the problems and challenges involved in improving the devices and long-term treatments were discussed in detail.

In this paper, we present a stent antenna for intravascular monitoring and implantable wireless applications that employ the entire stent as an antenna. The main contribution of this work was the manipulation of the current distributions of the stent for good radiation performance with a short stent length by exploiting a single connector between each unit of the stent. Unlike a general stent, wherein each unit is connected with multiple connectors, our proposed stent can achieve good EM radiation, maintain good mechanical strength, and remain within fracture limits during balloon expansions. A prototype was designed, fabricated, and experimentally examined with an EM anechoic chamber. The fabricated stent antenna demonstrated an omnidirectional radiation pattern, a gain of 1.38 dBi, and a radiation efficiency of 74.5% at the resonant frequency of 2.07 GHz. The results of this research should contribute to the development of implantable wireless communications and intravascular monitoring of cardiovascular diseases.

The interaction of biomaterials with blood leads to cellular as well as humoral reactions, which can result in an unwanted inflammation and activation of coagulation and/or fibrinolysis. Thus, the development of biomaterials with an improved hemocompatibility increases the tolerability and minimizes unwanted side effects, such as thrombus formation. Therefore, during the development of new blood-contacting medical devices, not only the mechanical and chemical characteristics should play an important role, but also the hemocompatibility. Furthermore, to prove the safety and reliability of new products, hemocompatibility analyses should include appropriate references and follow the ISO 10993-4 standard.

There is currently no standardized test method for in vitro dynamic thrombogenicity assessment of medical devices and biomaterials. This tool will effectively enable users to differentiate device materials with different thrombogenic potentials against standard negative and positive control materials and a marketed comparator device with known thrombogenicity profile.

These results demonstrated that multiple animal blood sources (particularly donor ovine and bovine blood) may be suitable alternatives to fresh human blood for dynamic thrombogenicity testing when appropriate control materials and donor-specific anticoagulation levels are used.

Many people overlook common lifestyle factors that impact their heart health. The survey, conducted by Ipsos, reveals around three in 10 adults are unaware that alcohol (32 percent), smoking (27 percent), and lack of sleep (27 percent) are linked to heart disease.

The interaction of biomaterials with blood leads to cellular as well as humoral reactions, which can result in an unwanted inflammation and activation of coagulation and/or fibrinolysis. Thus, the development of biomaterials with an improved hemocompatibility increases the tolerability and minimizes unwanted side effects, such as thrombus formation. Therefore, during the development of new blood-contacting medical devices, not only the mechanical and chemical characteristics should play an important role, but also the hemocompatibility. Furthermore, to prove the safety and reliability of new products, hemocompatibility analyses should include appropriate references and follow the ISO 10993-4 standard.

Acute coronary syndrome (ACS) remains a major challenge in clinical practice, requiring rapid and effective antithrombotic treatment to mitigate adverse ischemic events while minimizing the risk of bleeding. In recent years, results from several clinical trials addressing this issue through various approaches have substantially improved the treatment landscape for patients presenting with ACS. The emergence of new, potent P2Y12 inhibitors has significantly enhanced thrombotic risk reduction and different strategies for de-escalating and shortening dual antiplatelet therapy (DAPT) have demonstrated promising outcomes in reducing bleeding rates. Furthermore, data from ongoing trials focusing on novel therapeutic agents and investigating alternative treatment strategies to optimize outcomes for ACS patients are expected in the next few years. In this review, we summarize the current knowledge and emphasize the critical role of individualized treatment approaches tailored to patient-specific risk factors and individual clinical scenarios.

Despite substantial advances in stent technology, ISR remains the primary cause of target lesion failure after PCI. The available evidence supports the use of DCB angioplasty and DES implantation as first-line therapies for ISR. Nonetheless, the choice between DES and DCB should be individualized based on clinical, anatomical, and technical factors. In this regard, intravascular imaging with IVUS and OCT can be useful for identifying the primary mechanisms leading to ISR and guiding the interventional strategy during PCI. Moreover, emerging combined approaches employing lesion modification with cutting/scoring balloons, intravascular lithotripsy, rotational atherectomy, or excimer laser in association with DCB or DES can be advantageous in the treatment of specific patterns of ISR. Further high-quality data are needed to define the differential effectiveness and safety of contemporary DCBs and DESs, the long-term clinical outcomes, and whether there are preferential clinical and anatomic conditions for the use of one device over the other.

This product is suitable for patients with primary early to moderate open-angle glaucoma who are unable to tolerate or are unsuitable for traditional filtering surgery, and who, under static gonioscopy, have fully open angles, have had inadequate response or are intolerant to medication alone, and for whom angle laser therapy cannot control disease progression or is deemed inappropriate by the physician. It is also intended for patients who cannot undergo or are ineligible for angle laser therapy, and who require intraocular pressure (IOP) reduction in conjunction with cataract surgery.

Despite the abundance of research examining the effects of coffee, tea, and alcohol on inflammatory diseases, there is a notable absence of conclusive evidence regarding their direct causal influence on circulating inflammatory cytokines. Previous studies have primarily concentrated on established cytokines, neglecting the potential impact of beverage consumption on lesser-studied but equally important cytokines.